GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » ROIC %

CNBX (CNBX Pharmaceuticals) ROIC % : -16.38% (As of Aug. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. CNBX Pharmaceuticals's annualized return on invested capital (ROIC %) for the quarter that ended in Aug. 2024 was -16.38%.

As of today (2024-12-15), CNBX Pharmaceuticals's WACC % is 1.65%. CNBX Pharmaceuticals's ROIC % is -41.36% (calculated using TTM income statement data). CNBX Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


CNBX Pharmaceuticals ROIC % Historical Data

The historical data trend for CNBX Pharmaceuticals's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals ROIC % Chart

CNBX Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.65 -142.50 -124.88 -46.68 -40.03

CNBX Pharmaceuticals Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.47 -43.43 -57.99 -47.04 -16.38

Competitive Comparison of CNBX Pharmaceuticals's ROIC %

For the Biotechnology subindustry, CNBX Pharmaceuticals's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's ROIC % distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's ROIC % falls into.



CNBX Pharmaceuticals ROIC % Calculation

CNBX Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Aug. 2024 is calculated as:

ROIC % (A: Aug. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Aug. 2023 ) + Invested Capital (A: Aug. 2024 ))/ count )
=-0.583 * ( 1 - 0% )/( (1.618 + 1.295)/ 2 )
=-0.583/1.4565
=-40.03 %

where

CNBX Pharmaceuticals's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Aug. 2024 is calculated as:

ROIC % (Q: Aug. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: May. 2024 ) + Invested Capital (Q: Aug. 2024 ))/ count )
=-0.212 * ( 1 - 0% )/( (1.293 + 1.295)/ 2 )
=-0.212/1.294
=-16.38 %

where

Note: The Operating Income data used here is four times the quarterly (Aug. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CNBX Pharmaceuticals's WACC % is 1.65%. CNBX Pharmaceuticals's ROIC % is -41.36% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


CNBX Pharmaceuticals ROIC % Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary